Raven Biotechnologies Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $25M

Raven Biotechnologies General Information

Description

Developer of monoclonal antibody therapeutics intended to treat cancer. The company's lead product candidate, RAV12, targets adenocarcinomas and simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them, identifying novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane for the treatment of gastrointestinal and other cancers.

Contact Information

Website
www.ravenbio.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1140 Veterans Boulevard
  • South San Francisco, CA 94080
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Macrogenics
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1140 Veterans Boulevard
  • South San Francisco, CA 94080
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Raven Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 17-Jul-2008 $25M Completed Generating Revenue
8. Merger/Acquisition 01-Mar-2008 Cancelled Generating Revenue
7. Later Stage VC 12-Nov-2007 Completed Generating Revenue
6. Later Stage VC (Series D) 12-Oct-2005 Completed Clinical Trials - General
5. Later Stage VC 28-Oct-2004 Completed Clinical Trials - General
4. Later Stage VC (Series C) 13-Mar-2003 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 08-Jan-2001 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Jan-2000 Completed Pre-Clinical Trials
To view Raven Biotechnologies’s complete valuation and funding history, request access »

Raven Biotechnologies Patents

  • 157

    Total Documents Applications and Grants

  • Total Patents Families

  • 29

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Raven Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2675521-A1 Human cancer stem cells Active 22-Jan-2007
CA-2675521-C Human cancer stem cells Inactive 22-Jan-2007
WO-2008091908-A2 Human cancer stem cells Inactive 22-Jan-2007
WO-2008091908-A3 Human cancer stem cells Inactive 22-Jan-2007
WO-2008066691-A2 Tes7 and antibodies that bind thereto Inactive 08-Nov-2006 G01N33/5758
To view Raven Biotechnologies’s complete patent history, request access »

Raven Biotechnologies Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bear Stearns Health InnoVentures Management Venture Capital Minority
Biogen Corporation Minority
Cercano Management PE/Buyout Minority
Cogene Ventures Venture Capital Minority
GE Life Science and Technology Finance Corporation Minority
You’re viewing 5 of 16 investors. Get the full list »

Ready to get started?

Request a free trial

Raven Biotechnologies FAQs

  • When was Raven Biotechnologies founded?

    Raven Biotechnologies was founded in 1999.

  • Where is Raven Biotechnologies headquartered?

    Raven Biotechnologies is headquartered in South San Francisco, CA.

  • What industry is Raven Biotechnologies in?

    Raven Biotechnologies’s primary industry is Biotechnology.

  • Is Raven Biotechnologies a private or public company?

    Raven Biotechnologies is a Private company.

  • What is the current valuation of Raven Biotechnologies?

    The current valuation of Raven Biotechnologies is .

  • What is Raven Biotechnologies’s current revenue?

    The current revenue for Raven Biotechnologies is .

  • How much funding has Raven Biotechnologies raised over time?

    Raven Biotechnologies has raised $157M.

  • Who are Raven Biotechnologies’s investors?

    Bear Stearns Health InnoVentures Management, Biogen, Cercano Management, Cogene Ventures, and GE Life Science and Technology Finance are 5 of 16 investors who have invested in Raven Biotechnologies.

  • When was Raven Biotechnologies acquired?

    Raven Biotechnologies was acquired on 17-Jul-2008.

  • Who acquired Raven Biotechnologies?

    Raven Biotechnologies was acquired by Macrogenics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process